<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955731</url>
  </required_header>
  <id_info>
    <org_study_id>62036</org_study_id>
    <nct_id>NCT03955731</nct_id>
  </id_info>
  <brief_title>OCT Guided Magmaris RMS in STEMI</brief_title>
  <acronym>BESTMAG</acronym>
  <official_title>Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction With the Drug-eluting Resorbable Magnesium Scaffold: the BEST- MAG Multicentre Study. (BElgian ST-segment Elevation Myocardial Infarction Treatment With Resorbable MAGnesium Scaffold).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Charleroi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jolimont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital St Luc, Brussels</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Dinant Godinne - UCL Namur</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Le centre hospitalier EpiCURA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Régional de la Citadelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous treatment of coronary artery disease depends on the implantation of stents
      within diseased coronary segments. Compared with conventional bare-metal and drug- eluting
      stents, which remain permanently within the coronary anatomy, bioresorbable scaffolds (BRS)
      offer several potential advantages due to its resorbable properties. The resorbable magnesium
      scaffold Magmaris has demonstrated favourable outcomes in patients with stable coronary
      artery disease. In particular, in comparison to polymeric bioresorbable scaffolds, no cases
      of stent thrombosis have been reported in over two years of follow-up suggesting that
      magnesium-based resorbable scaffolds have low thrombogenicity and might be particularly
      beneficial for patients presenting with ST- segment myocardial infarction. A recent pilot
      study in eighteen patients supports this concept, which has led to the development of the
      proposed prospective multicentre study including intra-coronary imaging with long-term
      clinical follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A device oriented composite endpoint (DOCE) including cardiac death, target vessel myocardial infarction (attributable to the culprit lesion) and ischemic-driven target lesion revascularization (TLR) within 12 months after the index procedure.</measure>
    <time_frame>1 year</time_frame>
    <description>DOCE at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success defined as the delivery and deployment of RMS at the intended target lesion with a final residual stenosis ≤20% by visual estimation.</measure>
    <time_frame>in-hospital</time_frame>
    <description>Procedure succes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOCE at 1-,6- and 24-months follow-up periods.</measure>
    <time_frame>2 years</time_frame>
    <description>DOCE at 1,6 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite or probable scaffold thrombosis.</measure>
    <time_frame>2 years</time_frame>
    <description>incidence scaffold thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel healing assessment through an angiographic with OCT follow- up procedure at 15 months in predetermined participating centres</measure>
    <time_frame>15 months</time_frame>
    <description>Healing characteristics on OCT evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death, cardiac death, non-TVR, any revascularization at 1, 6, 12 and 24 months.</measure>
    <time_frame>2 years</time_frame>
    <description>MACE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Single study arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>STEMI Patients treated with Magmaris resorbable magnesium scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magmaris resorbable magnesium scaffold</intervention_name>
    <description>Implantation of Magmaris resorbable magnesium scaffold</description>
    <arm_group_label>Single study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients presenting with a ST-elevation myocardial infarction (STEMI) with symptoms
             onset &lt;24 hours or with ongoing symptoms.

          2. Signed patient informed consent.

        Exclusion Criteria:

          1. Age &lt; 18 or &gt; 70 years.

          2. Pregnancy or breastfeeding.

          3. Cardiogenic shock.

          4. Creatinine clearance ≤30 ml/min/1.73 m2 (as calculated by MDRD formula for estimated
             GFR) and not on dialysis. Note: chronic dialysis dependent patients are eligible for
             enrolment regardless of creatinine clearance.

          5. Infarct-artery reference diameter &lt; 2.7 or &gt; 4.0 mm (within the segment of the culprit
             lesion) by visual estimation, and OCT infarct-artery distal reference mean lumen
             diameter &lt; 2.7 or &gt; 3.7 mm

          6. Non-optimal vessel preparation after predilatation: residual stenosis &gt;30%.

          7. Culprit lesion length &gt; 21 mm.

          8. Culprit lesion located within a previously stented segment (stent thrombosis or
             in-stent restenosis).

          9. Culprit lesion involving a saphenous vein graft.

         10. Culprit lesion involving a bifurcation with an intended two-stent implantation
             strategy.

         11. Ostial right coronary artery

         12. Severe calcification or tortuosity of the infarct-related artery.

         13. Absolute contraindication to a 12 months dual antiplatelet therapy.

         14. Life expectancy &lt; 3 years.

         15. Patients taking oral anticoagulant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Johan Bennett, Dr.</last_name>
    <phone>+3216342465</phone>
    <email>johan.bennett@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johan Bennett</name>
      <address>
        <city>Leuven</city>
        <state>Brabant</state>
        <zip>3001</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Bennett</last_name>
      <phone>479293854</phone>
      <phone_ext>479293854</phone_ext>
      <email>johan.bennett@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Keir McCutcheon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

